ID: ALA4091545

Max Phase: Preclinical

Molecular Formula: C22H25N3O6

Molecular Weight: 427.46

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1cc(OC)c2c(=O)[nH]c(-c3ccc(OCCCCCC(=O)NO)cc3)nc2c1

Standard InChI:  InChI=1S/C22H25N3O6/c1-29-16-12-17-20(18(13-16)30-2)22(27)24-21(23-17)14-7-9-15(10-8-14)31-11-5-3-4-6-19(26)25-28/h7-10,12-13,28H,3-6,11H2,1-2H3,(H,25,26)(H,23,24,27)

Standard InChI Key:  LSJHECNNUWKAFR-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 427.46

Molecular Weight (Monoisotopic): 427.1743

AlogP: 3.05

#Rotatable Bonds: 10

Polar Surface Area: 122.77

Molecular Species: NEUTRAL

HBA: 7

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 8.84

CX Basic pKa: 3.10

CX LogP: 2.24

CX LogD: 2.22

Aromatic Rings: 3

Heavy Atoms: 31

QED Weighted: 0.26

Np Likeness Score: -0.37

References

1. Shao M, He L, Zheng L, Huang L, Zhou Y, Wang T, Chen Y, Shen M, Wang F, Yang Z, Chen L..  (2017)  Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.,  27  (17): [PMID:28765013] [10.1016/j.bmcl.2017.07.054]

2. Liu T,Wan Y,Xiao Y,Xia C,Duan G.  (2020)  Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.,  63  (17): [PMID:32320239] [10.1021/acs.jmedchem.0c00491]

Source

Source(1):

• Scientific Literature